Danaher Corporation Q2 FY2025 earnings call

• CFO Succession: Matt Gugino to succeed Matt McGrew as CFO in Feb 2026, with McGrew transitioning to executive vice president.
• Second Quarter Results: Sales $5.9B, 1.5% core revenue growth. Gross profit margin 59.3%, adjusted operating profit margin 27.3% flat YOY. Adjusted diluted net earnings per share $1.80, up ~5% YOY. Free cash flow $1.1B in Q2, $2.2B H1.
• New Product Launches: Syteva's protein A resins, Leica Biosystems' partnership with AstraZeneca, Xenotov 8600 in mass spectrometry.
• Bioprocessing Trends: Consumables led growth, equipment declined but funnel improving; strong development pipeline and commercial production support high single-digit long-term growth.
• Life Sciences Trends: Instrument businesses declined, China stimulus activity firming up, genomics consumables affected by funding.
• Diagnostics Trends: Clinical diagnostics up outside China, Cepheid's non-respiratory revenue growing.

Biotechnology Segment: Core revenue increased 6%. Bioprocessing saw high single-digit growth with consumables leading at low double-digit growth, while equipment declined due to capacity absorption and trade uncertainty. Discovery and medical down low single digits. Life Sciences Segment: Core revenue decreased 2.5%. Instrument businesses collectively declined low single digits. Genomics consumables declined due to lower demand from large customers and funding pressure. China stimulus activity led to firming in orders. Diagnostics Segment: Core revenue increased 2%. Clinical diagnostics up with mid-single-digit growth outside China. Cepheid's respiratory revenue modestly better than expected, non-respiratory revenue grew double digits.

• Full-year 2025 core revenue growth expected ~3%. Raised adjusted diluted net EPS guidance to $7.70-$7.80 from $7.60-$7.75. Q3 core revenue expected low single-digit growth, adjusted operating profit margin ~25.5%.
• Bioprocessing expects high single-digit growth for the year. Life sciences expects second half to be up positive low singles due to new product introductions and China firming.

• Global trade tensions affecting pharma capacity decisions.
• Volume-based procurement and reimbursement changes in China impacting diagnostics.
• Tariff exposure, though efforts to offset tariffs.
• Uncertainty in gene therapy market and macroeconomic environment.

Q: Michael Ryskin asked about bioprocess order trends, book to bill, and biotech vs pharma.

A: Rainer Blair responded on order trends, book to bill around 1, and trends by segment.

Q: Doug Schnickner asked about bioprocessing assumptions in guidance, pricing, and segment shifts.

A: Matt McGrew addressed bioprocessing growth expectations, pricing, and segment differences.

Q: Scott Davis asked about structural costs and early-stage biotech outlook.

A: Rainer Blair discussed structural cost progress and early-stage biotech dynamics.

Q: Tycho Peterson asked about guidance increments, life sciences step up, and China volume-based procurement.

A: Matt McGrew and Rainer Blair spoke on guidance, life sciences step-up, and China volume-based procurement status.

Q: Vijay Kumar asked about biotech guidance acceleration and 2026 outlook.

A: Matt McGrew and Rainer Blair discussed biotech guidance and 2026 preliminary thoughts.

Q: Puneet Souda asked about tariff updates and gene therapy exposure.

A: Matt McGrew and Rainer Blair addressed tariff exposure and gene therapy risk.

Q: Dan Leonard asked about China trends and FX impact on guidance.

A: Matt McGrew and Rainer Blair spoke on China trends and FX impact.

Q: Dan Brennan asked about bioprocess orders and Saffia respiratory trends.

A: Rainer Blair and Matt McGrew discussed bioprocess orders and Saffia respiratory outlook.

Q: Rachel Vatsendale asked about bioprocessing equipment recovery and respiratory rate revisiting.

A: Rainer Blair and Matt McGrew addressed bioprocessing equipment timing and respiratory rate revisiting